Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 | WAPE

Back All news

Newsfiscal.ai

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Oct 23, 2026, 18:02 ET · Published

View source

Article summary

Immutep Limited reported health-related quality of life (HRQoL) data from its investigator-initiated EFTISARC-NEO Phase II trial, which is being presented at the ESMO Congress 2026.

An excerpt from the original article.

Related companies

Immutep Limited American Depositary SharesIMMPView stock

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Article summary

Related companies

Analyzed by WAPE AI.

Comments —